Early ADME High Throughput Screening

Modern drug discovery laboratories rely heavily on the quality and accuracy of early in vitro and in vivo studies to select drug candidates. The high cost of R&D and fast pace with which modern medicinal chemists can synthesize new compounds places a high demand on early ADME/PK groups. To help improve the discovery pipeline, drug discovery labs must gather more information on a greater number of these new chemical entities in less time. Hence the foundation for success in early ADME/PK groups is linked to the throughput and quantitative sensitivity achievable with their compound optimizations.
To address the needs of the early ADME/PK laboratory, AB SCIEX has developed DiscoveryQuantTM Software for high throughput quantitative workflows. Combining the AB SCIEX high performance Triple QuadTM or QTRAP® LC MS/MS portfolio with the innovative DiscoveryQuantTM Software offers high throughput ion path optimization in conjunction with fast and efficient workflows for running quantitative studies. Conceived by the pharmaceutical industry, for the pharmaceutical industry.
With AB SCIEX DiscoveryQuantTM Software the industry defining Triple QuadTM and QTRAP® LC MS/MS portfolio, it is possible to implement a very comprehensive high throughput early ADME HTS solution that streamlines the drug discovery process by providing enhanced efficiency and productivity
- Automated flow injection based optimization of ion path parameters for both parent and fragment ions
- Capable of automated optimization up to 7 different MRM transitions per compound
- Optimized parameters are stored to local database & can be uploaded to global database for file sharing
- Ability to build MRM methods, set up batches, run and integrate data and generate results without using AnalystTM Software
- Built-in saturation control


















